GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioMedica PLC (LSE:OXB) » Definitions » Forward PE Ratio

Oxford BioMedica (LSE:OXB) Forward PE Ratio : 0.00 (As of Jun. 07, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Oxford BioMedica Forward PE Ratio?

Oxford BioMedica's Forward PE Ratio for today is 0.00.

Oxford BioMedica's PE Ratio without NRI for today is 0.00.

Oxford BioMedica's PE Ratio for today is 0.00.


Oxford BioMedica Forward PE Ratio Historical Data

The historical data trend for Oxford BioMedica's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioMedica Forward PE Ratio Chart

Oxford BioMedica Annual Data
Trend 2017-12 2018-12 2019-12 2020-12 2021-12 2022-04
Forward PE Ratio
181.82 40.65 46.73 90.91 40.16 250.00

Oxford BioMedica Semi-Annual Data
2017-09 2017-12 2018-03 2018-06 2018-09 2018-12 2019-03 2019-06 2019-09 2019-12 2020-03 2020-06 2020-09 2020-12 2021-03 2021-06 2021-09 2021-12 2022-03
Forward PE Ratio 161.29 181.82 232.56 81.97 60.98 40.65 61.35 57.47 25.97 46.73 72.99 91.74 909.09 90.91 108.70 86.21 70.92 40.16 28.99

Competitive Comparison of Oxford BioMedica's Forward PE Ratio

For the Biotechnology subindustry, Oxford BioMedica's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxford BioMedica's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioMedica's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Oxford BioMedica's Forward PE Ratio falls into.



Oxford BioMedica Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Oxford BioMedica  (LSE:OXB) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Oxford BioMedica Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Oxford BioMedica's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxford BioMedica (LSE:OXB) Business Description

Traded in Other Exchanges
Address
Windrush Court, Transport Way, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a player in the healthcare market in the United Kingdom. As a biopharmaceutical company, it focuses on the field of immunotherapy by managing a platform of technologies for designing gene-based medicines. The company's operating segments include the Platform segment consists of the revenue-generating bioprocessing and process development activities undertaken for third parties. Its Product segment consists of the clinical and preclinical development of in vivo and ex vivo gene and cell therapy products. The company derives the maximum revenue from the Platform segment. Its Platform includes LentiVector, LentiStable, TRiPSystem, SecNuc, Analytics, and others. Geographically, it generates the majority of its revenue from Europe.

Oxford BioMedica (LSE:OXB) Headlines

No Headlines